AMARIN CORP PLC\UK (AMRN) Guidance & Earnings Results

On 2026-07-29 AMARIN CORP PLC\UK reaffirmed guidance: "Expects continued growth in international markets, maintenance of U.S. market share, improved OPEX profile, positive cash flow…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AMRNAMARIN CORP PLC\UKFollow AMRN — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 261.2M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 27 Oct, in 3 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Reaffirmed	Expects continued growth in international markets, maintenance of U.S. market share, improved OPEX profile, positive cash flow generation · full year
29 Apr 26	Reaffirmed	Full year 2026 positive cash flow expected · full year
8 Jan 26	Raised	FY2025 net revenue $212-217M; Q4 2025 net revenue $48-53M; restructuring costs $37-40M (up from $30-37M); positive cash flow achieved in Q4 2025 (ahead of prior 2026 guidance); full OPEX savings of $70M by mid-2026. · full year

AMARIN CORP PLC\UK — questions

What guidance did AMARIN CORP PLC\UK give?: On 2026-07-29: "Expects continued growth in international markets, maintenance of U.S. market share, improved OPEX profile, positive cash flow generation"
When does AMARIN CORP PLC\UK report earnings?: AMARIN CORP PLC\UK's next earnings report is expected on 2026-10-27.

Every figure on this page comes from AMARIN CORP PLC\UK's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.